Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use WASKYRA® safely and effectively. See full prescribing information for WASKYRA®.WASKYRA® (etuvetidigene autotemcel) suspension, for intravenous useInitial U.S. Approval: 2025
Medication labelWhy this: Advisory · dailymed-prescription
WASKYRA® is indicated for the treatment of pediatric patients aged 6 months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene and for whom hematopoietic stem cell transplantation (HSCT) is appropriate and no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available.
- generic_name
- etuvetidigene autotemcel
- product_names
- Etuvetidigene autotemcel
- ndc
- 87233-0100, 87233-0100-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en